Abstracts of the 2021 Cannabis Clinical Outcomes Research Conference

Proceedings of the 2021 Cannabis Clinical Outcomes Research Conference

Medical Cannabis and Cannabinoids ◽

10.1159/000519037 ◽

2021 ◽

pp. 1-4

Author(s):

Amie J. Goodin ◽

Debbie L. Wilson ◽

Robert L. Cook ◽

Yan Wang ◽

Joshua Brown ◽

...

Keyword(s):

United States ◽

Clinical Outcomes ◽

Outcomes Research ◽

Medical Marijuana ◽

The United States ◽

State Legislature ◽

Scientific Meeting ◽

Research Conference ◽

Policy Practice ◽

Common Barriers

The Cannabis Clinical Outcomes Research Conference (CCORC) 2021 was held virtually on April 8 and 9, 2021. The conference was hosted by the Consortium for Medical Marijuana Clinical Outcomes Research, a research organization instituted by the state legislature of Florida in the United States. The inaugural annual CCORC 2021 was organized as a scientific meeting to foster and disseminate research on medical marijuana (MM) clinical outcomes, while promoting engagement among MM researchers, patients, clinicians, policymakers, and industry partners. Key conference themes included: (a) the disconnect between policy, practice, and evidence and steps towards reconciliation, (b) approaches to overcome common barriers to MM research, and (c) the use of focused translational approaches utilizing both mechanistic and clinical research methodology to tackle the complexities of MM outcomes. CCORC 2022 is planned for spring 2022 in Orlando, Florida, United States.

Download Full-text

Practice-based Outcomes Research: Crucial, Feasible, and Neglected

PEDIATRICS ◽

10.1542/peds.97.1.113 ◽

1996 ◽

Vol 97 (1) ◽

pp. 113-114

Author(s):

Jerry Avorn

Keyword(s):

Health Care ◽

Clinical Outcomes ◽

Outcomes Research ◽

Cost Containment ◽

American Health Care System ◽

American Health Care ◽

Experimental Subjects ◽

Contemporary Medicine ◽

Pharmacologic Therapies

The article from the Vermont-Oxford Neonatal Network1 in this issue of Pediatrics comparing two surfactant preparations represents an important case study of a central issue in contemporary medicine: the need for rigorous, even-handed evaluation of competing therapies. Even at a time in which patients and payers are expecting ever-higher standards for clinical outcomes, and policymakers and insurers are demanding more and more stringent cost containment, the American health care system lacks a coherent mechanism for assembling and analyzing the data needed to meet these goals. For pharmacologic therapies, the Food and Drug Administration (FDA) prefers that mew agents be tested against placebos whenever possible, unless this would result in harm to experimental subjects.

Download Full-text